The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Open accessAbstract
BACKGROUND: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per megabase). METHODS: We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. Tumor mutational burden was determined by the FoundationOne CDx assay. RESULTS: Progression-free survival among patients with a high tumor mutational burden was significantly longer with nivolumab plus ipilimumab than with chemotherapy. The 1-year progression-free survival rate was 42.6% with nivolumab plus ipilimumab versus 13.2% with chemotherapy, and the median progression-free survival was 7.2 months (95% confidence interval [CI], 5.5 to 13.2) versus 5.5 months (95% CI, 4.4 to 5.8) (hazard ratio for disease progression or death, 0.58; 97.5% CI, 0.41 to 0.81; P<0.001). The objective response rate was 45.3% with nivolumab plus ipilimumab and 26.9% with chemotherapy. The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within subgroups, including patients with a PD-L1 expression level of at least 1% and those with a level of less than 1%. The rate of grade 3 or 4 treatment-related adverse events was 31.2% with nivolumab plus ipilimumab and 36.1% with chemotherapy. ical; CheckMate 227 ClinicalTrials.gov number, NCT02477826 .). CONCLUSIONS: Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level. The results validate the benefit of nivolumab plus ipilimumab in NSCLC and the role of tumor mutational burden as a biomarker for patient selection. (Funded by Bristol-Myers Squibb and Ono Pharmaceut
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, limited biomarkers, such as PD-L1 expression (88) and tumor mutation load (TMB) (89–91), are clinically used to predict the immunotherapy benefit.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,002
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
Pouyiourou, M., Kraft, B. N., Wohlfromm, T., Ståhl, M., Kubuschok, B., Löffler, H., Hacker, U. T., Hübner, G., Weiss, L., Bitzer, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42400-5 · Cited by 42
Yin, X., Song, X., Deng, W., BLAKE, N. W., Luo, X., & Meng, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1483454 · Cited by 44
Corral, J., Majem, M., Rodríguez‐Abreu, D., Carcereny, E., Cortes, A. A., Llorente, M. D. M., López-Picazo, J. M., García, Y. G., Dómine, M., & Criado, M. P. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02053-7 · Cited by 42
Recent advances in the molecular landscape of lung neuroendocrine tumors
Pelosi, G., Bianchi, F., Hofman, P. M., Pattini, L., Ströbel, P., Calabrese, F., Naheed, S., Holden, C., Cave, J., Bohnenberger, H., et al. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1595593 · Cited by 42
Califano, R., Gomes, F., Ackermann, C. J., Rafee, S., Tsakonas, G., & Ekman, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.010 · Cited by 42
IL-17A and IL-17F orchestrate macrophages to promote lung cancer
Ferreira, N. L. C., Mesquita, I., Baltazar, F., Silvestre, R., & Granja, S. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00510-y · Cited by 42
Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
Shao, J., Wang, C., Ren, P., Jiang, Y., Tian, P., & Li, W. (2020) · Bioscience Reports · doi:10.1042/bsr20192347 · Cited by 46
Popat, S., Grohé, C., Corral, J., Reck, M., Novello, S., Gottfried, M., Radonjic, D., & Kaiser, R. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.009 · Cited by 42
Self-citationZizzari, I. G., Filippo, A. D., Scirocchi, F., Pietro, F. R. D., Rahimi, H., Ugolini, A., Scagnoli, S., Vernocchi, P., CHIERICO, F. D., Putignani, L., et al. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040208 · Cited by 44
Meng, G., Liu, X., Ma, T., Lv, D., & Sun, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263629 · Cited by 42
A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade
Ngoi, N. Y. L., Peng, G., & Yap, T. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-025136 · Cited by 42
Lung cancer in never smokers: Tumor immunology and challenges for immunotherapy
de Alencar, V. T. L., Figueiredo, A. B., Corassa, M. P., Gollob, K. J., & de Lima, V. C. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984349 · Cited by 47
Schenker, M., Burotto, M., Richardet, M. E., Ciuleanu, T., Gonçalvès, A., Steeghs, N., Schöffski, P., Ascierto, P. A., Maio, M., Lugowska, I. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008872 · Cited by 43
Self-citationNew windows open for immunotherapy in lung cancer
Hendriks, L. E. L., & Besse, B. (2018) · Nature · doi:10.1038/d41586-018-05312-9 · Cited by 41
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
Miura, Y., & Sunaga, N. (2018) · Cancers · doi:10.3390/cancers10080245 · Cited by 41
A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC
Carmichael, J. A., Mak, D. W.-S., & O’Brien, M. (2018) · Cancers · doi:10.3390/cancers10070236 · Cited by 42
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy
Rizk, E. M., Gartrell, R. D., Barker, L. W., Esancy, C. L., Finkel, G. G., Bordbar, D. D., & Saenger, Y. M. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.005 · Cited by 43
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Mhanna, L., Guibert, N. M., Milia, J., & Mazières, J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0652-3 · Cited by 43
Saigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 40
Effect and biomarker of Nivolumab for non–small-cell lung cancer
Wang, L., Zhao, D., Qin, K., Rehman, F. U., & Zhang, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109199 · Cited by 42
Wu, H., Wang, Z., Zhao, Q., Wang, F., & Xu, R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0681-2 · Cited by 42
Significant function and research progress of biomarkers in gastric cancer (Review)
Ye, D., Xu, G., Ma, W., Li, Y., Luo, W., Xiao, Y., Liu, Y., & Zhang, Z. (2019) · Oncology Letters · doi:10.3892/ol.2019.11078 · Cited by 43
Sung, S., Heymann, J. J., Crapanzano, J. P., Moreira, A. L., Shu, C. A., Bulman, W. A., & Saqi, A. (2020) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2020.04.014 · Cited by 42
Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside
Roy, S., Sethi, T. K., Taylor, D., Kim, Y. J., & Johnson, D. B. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5bt0420-585rr · Cited by 44
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
Duchemann, B., Remón, J., Naigeon, M., Mezquita, L., Ferrara, R., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., et al. (2020) · Cancers · doi:10.3390/cancers12123625 · Cited by 42
Zhou, Y., Xia, R., Xiao, H., Pu, D., Long, Y., Ding, Z., Liu, J., & Ma, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107296 · Cited by 42
The Current Lung Cancer Neoantigen Landscape and Implications for Therapy
Ye, L., Creaney, J., Redwood, A., & Robinson, B. W. S. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1624 · Cited by 42
Aamdal, E., Inderberg, E. M., Ellingsen, E. B., Rasch, W., Brunsvig, P. F., Aamdal, S., Heintz, K., Vodák, D., Nakken, S., Hovig, E. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663865 · Cited by 41
Xia, L., Guo, L., Kang, J. U., Yang, Y., Yao, Y., Xia, W., Sun, R., Zhang, S., Li, W., Gao, Y.-E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.759217 · Cited by 40
Zhou, C., Li, M., Wang, Z., An, D., & Li, B. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108353 · Cited by 41
Ke, H., Li, P., Li, Z., Zeng, X., Zhang, C., Luo, S., Chen, X., Zhou, X., Dong, S., Chen, S., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70175 · Cited by 41
Fernandez, E. M., Eng, K., Beg, S., Beltran, H., Faltas, B. M., Mosquera, J. M., Nanus, D. M., Pisapia, D. J., Rao, R. A., Robinson, B. D., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00400 · Cited by 39
The Discovery of Biomarkers in Cancer Immunotherapy
George, A. P., Kuzel, T. M., Zhang, Y., & Zhang, B. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.015 · Cited by 41
Gomes, F., Wong, M. L., Battisti, N. M. L., Kordbacheh, T., Kiderlen, M., Greystoke, A., & Luciani, A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0986-4 · Cited by 41
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 41
If small molecules immunotherapy comes, can the prime be far behind?
Zhang, J., Zhang, Y., Qu, B., Yang, H., Hu, S., & Dong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113356 · Cited by 40
Bongiovanni, A., Foca, F., Menis, J., Stucci, S. L., Artioli, F., Guadalupi, V., Forcignanò, R., Fantini, M., Recine, F., Mercatali, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697298 · Cited by 40
Insa, A., Martín-Martorell, P., Liello, R. D., Fasano, M., Martini, G., Napolitano, S., Vicidomini, G., Cappabianca, S., Franco, R., Morgillo, F., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103538 · Cited by 42
Biomarkers for predicting the efficacy of immune checkpoint inhibitors
Wang, C., Wang, H.-N., & Wang, L. (2022) · Journal of Cancer · doi:10.7150/jca.65012 · Cited by 39
Girard, N., Basse, C., Schrock, A. B., Ramkissoon, S. H., Killian, K. J., & Ross, J. S. (2022) · The Oncologist · doi:10.1093/oncolo/oyac115 · Cited by 41
Federico, A. D., Giglio, A. D., Gelsomino, F., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac205 · Cited by 40
Barlési, F., Isambert, N., Felip, E., Cho, B. C., Lee, D. H., Peguero, J. A., Jérusalem, G., Penel, N., Saâda-Bouzid, E., Garrido, P., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac253 · Cited by 40
Chaudhary, R., Quagliata, L., Jermann, P. M., Alborelli, I., Cyanam, D., Mittal, V., Tom, W., Au-Young, J. K., Sadis, S. E., & Hyland, F. C. L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.01 · Cited by 42
PD-1 Blockade in Early-Stage Lung Cancer
Rosner, S., Reuss, J. E., & Forde, P. M. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-025205 · Cited by 36
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer
Melosky, B. L., Juergens, R. A., Hirsh, V., McLeod, D., Leighl, N. B., Tsao, M., Card, P. B., & Chu, Q. S.-C. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0027 · Cited by 40
Leclerc, M., Mezquita, L., Nerville, G. G. D., Tihy, I., Malenica, I., Chouaïb, S., & Mami‐Chouaib, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01505 · Cited by 40
PD-1 Inhibitors in the Advanced Esophageal Cancer
Hong, Y., & Ding, Z. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01418 · Cited by 39
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
Wakabayashi, G., Lee, Y., Luh, F., Kuo, C.-N., Chang, W., & Yen, Y. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0588-8 · Cited by 39
Zhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 40
Dickhoff, C., Senan, S., Schneiders, F. L., Veltman, J. D., Hashemi, S. M. S., Daniels, J. M. A., Fransen, M. F., Heineman, D. J., Radonic, T., van de Ven, P. M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07263-9 · Cited by 39
Zhang, P., Liu, M., Cui, Y., Zheng, P., & Liu, Y. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa180 · Cited by 39
Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?
Sajjadi, E., Venetis, K., Scatena, C., & Fusco, N. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1150 · Cited by 40
Campbell, B. B., Galati, M. A., Stone, S. C., Riemenschneider, A. N., Edwards, M., Sudhaman, S., Siddaway, R., Komosa, M., Nunes, N. M., Nobre, L. F., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1050 · Cited by 40
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology
Sobhani, F., Robinson, R., Hamidinekoo, A., Roxanis, I., Somaiah, N., & Yuan, Y. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188520 · Cited by 41
Ayers, K. L., Mullaney, T., Zhou, X., Liu, J. J., Lee, K., Ma, M., Jones, S., Li, L., Redfern, A., Jappe, W., et al. (2021) · The Oncologist · doi:10.1002/onco.13780 · Cited by 40
Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics
Murchan, P., O’Brien, C. P., O’Connell, S., McNevin, C. S., Baird, A., Sheils, O. M., Broin, P. Ó., & Finn, S. P. (2021) · Diagnostics · doi:10.3390/diagnostics11081406 · Cited by 39
Akhbariyoon, H., Azizpour, Y., Esfahani, M. F., Firoozabad, M. S. M., Rad, M. R., Esfahani, K. S., Khoshavi, N., Karimi, N., Shirinisaz, A., Abedi, F., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108873 · Cited by 40
Bie, F., Tian, H., Sun, N., Zang, R., Zhang, M., Song, P., Liu, L., Peng, Y., Bai, G., Zhou, B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.769124 · Cited by 39
Hu, X., Zhu, H., Zhang, X., He, X., & Xu, X. (2021) · Cancer Medicine · doi:10.1002/cam4.4203 · Cited by 41
de Lima, V. C. C., Corassa, M. P., Saldanha, E. F., Freitas, H., Arrieta, O. G., Raez, L. E., Samtani, S., Ramos-Ramírez, M., Rojas, C., Burotto, M., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.06.010 · Cited by 44
Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics
Dwivedi, M., Tiwari, S., Kemp, E. H., & Begum, R. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10450 · Cited by 38
Wu, Z., Zhang, S., Li, L., Huang, Z., Huang, D., & Hu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.887383 · Cited by 38
Thummalapalli, R., Ricciuti, B., Bandlamudi, C., Muldoon, D. M., Rizvi, H. A., Elkrief, A., Luo, J., Alessi, J. V., Pecci, F., Lamberti, G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1207 · Cited by 38
Self-citationSholl, L. M., Awad, M., Basu Roy, U., Beasley, M. B., Cartun, R. W., Hwang, D. M., Kalemkerian, G., Lopez-Rios, F., Mino-Kenudson, M., Paintal, A., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0536-cp · Cited by 38
Wang, C., Liu, T.-C., Lai, P.-J., Muzakky, H., Wang, Y., Yu, M.-H., Wu, C.-H., & Chao, T. (2024) · Medical Image Analysis · doi:10.1016/j.media.2024.103372 · Cited by 41
Exploring optimal sequencing of radiation and immunotherapy combinations
Gunderson, A. J., & Young, K. H. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.07.005 · Cited by 39
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva
Thangarajah, F., Morgenstern, B., Pahmeyer, C., Schiffmann, L. M., Puppe, J., Mallmann, P. K., Hamacher, S., Buettner, R., Alidousty, C., Holz, B., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02915-1 · Cited by 38
Chahoud, J., Pickering, C. R., & Pettaway, C. A. (2019) · Current Opinion in Urology · doi:10.1097/mou.0000000000000640 · Cited by 38
Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed
Levinson, K. L., Dorigo, O., Rubin, K. M., & Moore, K. N. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237967 · Cited by 38
Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Scarpelli, M., Cimadamore, A., Antonio Lopez-beltran, B., Liang Cheng, C., Battelli, N., Montironi, R., et al. (2019) · Cancers · doi:10.3390/cancers11060830 · Cited by 37
Zhao, J., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000710 · Cited by 40
Steeghs, E. M. P., Kroeze, L. I., Tops, B. B. J., van Kempen, L. C. L. T., ter Elst, A., van Raaij, A. W. M., Hendriks-Cornelissen, S. J. B., Hermsen, M. J. W., Jansen, E. A. M., Nederlof, P. M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06785-6 · Cited by 37
Cui, P., Huang, D., Wu, Z., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Huang, Z., Chen, S., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920922033 · Cited by 38
Leprieur, E. G., Hélias‐Rodzewicz, Z., Kamga, P. T., Costantini, A., Julié, C., Corjon, A., Duménil, C., Dumoulin, J., Giraud, V., Labrune, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000527 · Cited by 40
Comprehensive molecular profiling broadens treatment options for breast cancer patients
Kawaji, H., Kubo, M., Yamashita, N., Yamamoto, H., Kai, M., Kajihara, A., Yamada, M., Kurata, K., Kaneshiro, K., Harada, Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3619 · Cited by 39
The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients
Zhou, F., Huang, Y., Cai, W., Li, J., Su, C., Ren, S., Wu, C., & Zhou, C. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.01.006 · Cited by 38
Current Advances in the Management of Adult Craniopharyngiomas
Lara-Velazquez, M. A., Mehkri, Y., Panther, E. J., Hernandez, J. S., Rao, D., Fiester, P. J., Makary, R., Rutenberg, M. S., Tavanaiepour, D., & Rahmathulla, G. (2022) · Current Oncology · doi:10.3390/curroncol29030138 · Cited by 39
NeoSplice: a bioinformatics method for prediction of splice variant neoantigens
Chai, S., Smith, C. C., Kochar, T. K., Hunsucker, S. A., Beck, W. A., Olsen, K. S., Vensko, S. P., II, Glish, G. L., Armistead, P. M., Prins, J. F., et al. (2022) · Bioinformatics Advances · doi:10.1093/bioadv/vbac032 · Cited by 37
Cucchiara, F., Petrini, I., Romei, C., Crucitta, S., Lucchesi, M., Valleggi, S., Scavone, C., Capuano, A., LIPERI, A. D., Chella, A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105643 · Cited by 39
Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
Yang, J., Yan, H., Zhang, Y.-X., Zhang, M., Ji, B., Tian, G., Guo, Y., Tang, M., Li, L., Guo, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.725938 · Cited by 37
Roh, W., Geffen, Y., Cha, H., Miller, M. L., Anand, S. K., Kim, J., Heiman, D. I., Gainor, J. F., Laird, P. W., Cherniack, A. D., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0432 · Cited by 37
Yuan, L., Sun, S., Zhang, Q., Li, H., Shen, Z., Hu, C., Zhao, X., Ye, L., Zheng, C.-H., & Huang, D.-S. (2024) · Future Generation Computer Systems · doi:10.1016/j.future.2024.05.030 · Cited by 39
Immune Checkpoint Blockade across the Cancer Care Continuum
Helmink, B. A., Gaudreau, P.-O., & Wargo, J. A. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.003 · Cited by 38
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
Villanueva, N., & Bazhenova, L. A. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618794133 · Cited by 37
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects
Long, L., Zhao, C., Muqimova, O., Zhao, X., Yang, J. L., & Chen, H. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-018-00746-5 · Cited by 33
Lim, S. M., Choi, J. W., Hong, M. H., Jung, D., Lee, C. Y., Park, S. Y., Shim, H. S., Sheen, S. S., Kwak, K. I., Kang, D. R., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.002 · Cited by 37
Second-line treatment options in hepatocellular carcinoma
Marino, D., Zichi, C., Audisio, M., Sperti, E., & Maïo, M. D. (2019) · Drugs in Context · doi:10.7573/dic.212577 · Cited by 37
Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors
Lü, S., Yu, Y., & Yang, Y. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s02 · Cited by 35
Lee, J., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.29 · Cited by 37
Self-citationLiu, J., Li, C., Seery, S., Yu, J., & Meng, X. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1746112 · Cited by 38
CD47 prevents the elimination of diseased fibroblasts in scleroderma
Lerbs, T., Cui, L., King, M. E., Chai, T., Muscat, C., Chung, L. S., Brown, R. A., Rieger, K. E., Shibata, T., & Wernig, G. (2020) · JCI Insight · doi:10.1172/jci.insight.140458 · Cited by 39
Zhang, N., Guoqing, W., Yu, X., Mi, Y., Xin, H., Li, X., & Wang, R. (2021) · BioMed Research International · doi:10.1155/2021/1780860 · Cited by 37
Dai, J., Jiang, M., He, K., Wang, H., Chen, P., Guo, H., Zhao, W., Lu, H. J., He, Y., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708294 · Cited by 38
Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
Luo, W., Wang, Z., Zhang, T., Yang, L., Xian, J., Li, Y., & Li, W. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab027 · Cited by 40
Wang, S., Yuan, P., Mao, B., Li, N., Ying, J., Tao, X., Tang, W., Zhang, L., Geng, X., Zhang, F., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00244-6 · Cited by 38
Liquid Biopsy: the Value of Different Bodily Fluids
Santos, V., Freitas, C., Fernandes, M. G., Sousa, C., Reboredo, C., Martins, N. A., Mosquera, J., Hespanhol, V. P., & Campelo, R. G. (2022) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0370 · Cited by 39
Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer
Russell, É., Conroy, M. J., & Barr, M. P. (2022) · Cells · doi:10.3390/cells11040605 · Cited by 37
Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M. J., Dubinett, S. M., Ferris, A. A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003956 · Cited by 46
Self-citationLiang, Y., He, H., Wang, W., Wang, H., Mo, S., Fu, R., Liu, X., Song, Q., Xia, Z., & Wang, L. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01648-z · Cited by 40
Cheng, Y., Bu, D., Zhang, Q., Sun, R., Lyle, S. R., Zhao, G., Dong, L., Li, H., Zhao, Y. C., Yu, J., et al. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.10.019 · Cited by 37
Metadata
- Authors
- Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., Borghaei, H., Ramalingam, S. S., Brahmer, J., Reck, M., O’Byrne, K. J., Geese, W. J., Green, G., Chang, H., Szustakowski, J., Bhagavatheeswaran, P., Healey, D., Fu, Y., Nathan, F., & Paz-Ares, L.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center Hospital, New York (M.D.H.); Prof. Dr. Ion Chiricuta Institute of Oncology and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Centrum Onkologii–Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland (A.P.); Seoul National University Bundang Hospital, Seoul, South Korea (J.S.L.); Ohio State University, Columbus (G.A.O.); Hôpital Sainte Musse, Toulon, France (C.A.-V.); Ospedale Santa Maria della Misericordia, Perugia,...
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-31
- Volume
- 378
- Issue
- 22
- Pages
- 2093-2104
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7193684
- OpenAlex
- W2797675588
- Cited by
- 3,063
- References
- 22
- Citations by year
- 2026: 100 · 2025: 184 · 2024: 222 · 2023: 289 · 2022: 419 · 2021: 499 · 2020: 559 · 2019: 542 · 2018: 247
- FWCI
- 174.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb, Inc.
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, ipilimumab, non-small cell lung cancer, tumor mutational burden, PD-L1 expression, immune checkpoint inhibitors, progression-free survival, chemotherapy comparison, stage IV lung cancer, treatment-related adverse events, treatment response biomarkers, objective response rate, immunotherapy biomarkers, safety and tolerability
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Biomarkers, Tumor, Disease-Free Survival, Kaplan-Meier Estimate, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
